Dr. Brun’s expertise in early and late-stage clinical development in the areas of autoimmune, neurological and renal diseases aligns well with Cabaletta’s burgeoning pipeline.
PHILADELPHIA, June 28, 2021 (GLOBE NEWSWIRE) – Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of modified T cell therapies for patients with self-induced diseases. B-cell-mediated immune systems, today announced the appointment of veteran biopharmacy leader Scott Brun, MD, to its board of directors. Dr. Brun has over 20 years of experience in drug development and business development, including serving as vice president and chief pharmaceutical development officer at AbbVie Inc., or AbbVie, and predecessor company, Abbott Laboratories, and Head of AbbVie Ventures, a venture capital fund responsible for investment opportunities.
“Scott is an accomplished physician and executive with a pharmaceutical perspective on early and advanced clinical development, strategic partnerships and investment experience, including particular expertise in clinical product development in the therapeutic areas of self-disease. immune, neurological and renal, aligns well with our rapidly moving pipeline. His expertise will be particularly valuable to Cabaletta as we advance our core program, DSG3-CAART, in mucosal pemphigus vulgaris, ”said Steven Nichtberger, MD, CEO and co-founder of Cabaletta. “We welcome him to the Board of Directors and look forward to his contribution to our strategic and operational objectives as we seek to increase shareholder value. “
Dr Brun spent two decades with AbbVie and Abbott Laboratories, the predecessor company, where he was most recently Vice President of Scientific Affairs and Director of AbbVie Ventures, a venture capital fund responsible for investment opportunities in the fields. AbbVie R&D therapies as well as technological platforms of interest. Previously, Dr Brun was Vice President and Head of Pharmaceutical Development. During his tenure, Dr Brun oversaw a global organization with responsibilities for AbbVie’s entire portfolio of compounds from the early and late stage clinical pre-registration pipeline as well as compounds marketed in the fields of oncology, neurology, immunology, kidney, infectious and female and male diseases. therapeutic areas of health. Earlier in his career, he held positions of increasing responsibility in drug development within the R&D organization of Abbott Laboratories. Dr Brun is currently President of Gold Mast Consulting, LLC, a consulting firm he founded to provide technical advice and strategic guidance related to biopharmaceutical research and development, pipeline portfolio management, marketing of new therapies and strategic communications related to R&D activities. Dr. Brun received his BS in Biochemistry from the University of Illinois at Urbana-Champaign and his MD from Johns Hopkins University School of Medicine. He completed his ophthalmology residency at the Massachusetts Eye and Ear Infirmary at Harvard Medical School.
“Based on a robust and elegant science platform, Cabaletta has the potential to revolutionize the autoimmune disease treatment landscape and I look forward to contributing to the board and joining the leadership team. as they seek to accomplish their mission of providing sustainable treatment for patients with B-cell mediated autoimmune diseases, ”said Scott Brun, MD
Dr. Brun will become a member of the Audit Committee and of the Nomination and Corporate Governance Committee. Dr Brun will succeed Brian Daniels, MD, who resigned from the board on June 24, 2021 and subsequently joined the scientific advisory board. Dr Daniels has served on the Cabaletta Board of Directors since October 2018.
“On behalf of the entire management team and colleagues on the Cabaletta Board of Directors, I would like to thank Dr. Daniels for his insights and thoughtful and in-depth questions over the past three years and for his service within from the administration board. His advice and guidance has proven to be invaluable. We are fortunate to be able to continue our engagement with Dr Daniels as a member of our Scientific Advisory Board, ”continued Dr Nichtberger.
About Cabaletta Bio
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of modified T-cell therapies, and exploring their potential to provide a profound and lasting treatment, possibly curative, to patients with autoimmune diseases in B-cell mediated. Cabaletta’s Selective B-Cell Ablation Platform (CABA ™) approach, in combination with Cabaletta’s proprietary technology, uses chimeric autoantibody receptor (CAAR) T cells ) designed to selectively bind and remove only specific autoantibody-producing B cells while sparing normal antibodies. producing B cells, essential for human health. The Company’s lead product candidate, DSG3-CAART, is being evaluated in the phase 1 clinical trial of DesCAARTes ™ as a potential treatment for patients with mucosal pemphigus vulgaris, a disease of its own. B cell-mediated prototypical immune system. The FDA granted Fast Track designation for DSG3-CAART in May 2020. For more information on the DesCAARTes ™ Phase 1 clinical trial, please visit www.clinicaltrials.gov. The Company’s primary preclinical product candidate, MuSK-CAART, is being investigated for IND and is intended as a potential treatment for patients with myasthenia gravis associated with MuSK. For more information, visit www.cabalettabio.com.
This press release contains “forward-looking statements” of Cabaletta within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the business plans and objectives of the company; expectations regarding the progress and results of its Phase 1 DesCAARTes ™ trial; the effectiveness and timing of product candidates that Cabaletta may develop, including in collaboration with academic partners; statements regarding regulatory filings regarding its development programs; and the expected contribution of our board members and officers to our operations and progress.
All forward-looking statements contained in this press release are based on management’s current expectations and beliefs regarding future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially. and unfavorably from those stated or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: Cabaletta’s ability to demonstrate sufficient evidence of safety, efficacy and tolerability in its clinical trials of DSG3-CAART; risks associated with unexpected safety or efficacy data observed in clinical studies; risks related to the impact of public health epidemics affecting the countries or regions in which we have operations or do business, such as COVID-19; and the risk that the initial or intermediate results of clinical studies will not be predictive of future results of future studies. For a discussion of these risks and uncertainties, as well as other important factors, any of which could cause Cabaletta’s actual results to differ from those contained in forward-looking statements, see the section entitled “Risk Factors” in Cabaletta’s most recent annual report. on Form 10-K as well as discussions of potential risks, uncertainties and other important factors in other documents filed by Cabaletta with the Securities and Exchange Commission. All information in this press release is as of the date of publication, and Cabaletta does not undertake to update this information, except as required by law.
Stern Investor Relations, Inc.